Back to Clinical Trials

Clinical Trials: Rheumatology


Source: Genentech, Inc.
This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will receive Rituxan therapy will be recruited. There is no protocol mandated treatment assignment in this study. Patients will be evaluated and treated according to their ... Read More
Last Updated: 25 Mar 2015
Source: Glostrup University Hospital, Copenhagen
Spondyloarthropathies (SpA) are often diagnosed with a considerable delay (often 8-10 years from symptom onset), because the available clinical, biochemical and radiological methods are not sufficiently sensitive. TNF-a antagonists have recently been introduced for treatment of SpA, and current data indicate a higher efficacy than previously available therapies. The improved treatment options have increased the need for improved methods for diagnosis, ... Read More
Last Updated: 26 Mar 2012
Source: Pfizer
The objective of this study is to identify any problems and questions with respect to the safety and efficacy of Xeljanz during the post-marketing period as required by the regulation of MFDS. Read More
Last Updated: 11 Jan 2017
Source: American College of Rheumatology
The RISE Registry is an enhanced version of the ACR's Rheumatology Clinical Registry (RCR) and allows for a simplified entry process, while establishing a best-in-class resource to manage your patient population and improve patient care. RISE provides participants with an infrastructure for robust quality improvement activities leading to improved patient outcomes, patient population management and quality reporting related to rheumatic diseases and drug ... Read More
Last Updated: 28 Aug 2014
Source: La Jolla Pharmaceutical Company
The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis. Read More
Last Updated: 21 Sep 2006
Source: Bristol-Myers Squibb
The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive Read More
Last Updated: 02 Jan 2014
Source: Hvidovre University Hospital
The study investigates different criteria for remission based on MRI and circulating biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates factors that affect disease activity, function and participation by use of different questionnaires. Read More
Last Updated: 09 Dec 2013
Source: Pfizer
The purpose of this study is to evaluate the efficacy and tolerability of pregabalin compared with placebo for management of fibromyalgia in adults. Read More
Last Updated: 18 Jan 2017
Source: Pfizer
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab. Read More
Last Updated: 07 Dec 2015
Source: Bristol-Myers Squibb
The purpose of this study is to determine whether switching to subcutaneous administration of abatacept will be safe in participants with rheumatoid arthritis who previously received long-term therapy with intravenous abatacept Read More
Last Updated: 16 Feb 2015
Source: Procter and Gamble
Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis. Read More
Last Updated: 06 Nov 2011
Source: American College of Rheumatology
The ACR Rheumatology Clinical Registry (RCR) is a tool developed to assist members in practice improvement, local population management, and efficient, successful participation in national quality programs. RCR integrates evidence-based quality measures aimed at improving care and drug safety for patients with rheumatoid arthritis, osteoarthritis, osteoporosis, gout and juvenile idiopathic arthritis. Read More
Last Updated: 28 Aug 2014
Source: University Hospital, Rouen
To detect by sonography relapse of disease activity prior to clinical symptoms in RA patients treated by rituximab. Read More
Last Updated: 20 Jan 2015
Source: Horizon Pharma Rheumatology LLC
The primary purpose of this study is to observe patients being treated with KRYSTEXXA in a standard healthcare setting in order to evaluate the frequency and severity of infusion reactions, anaphylaxis and immune complex related events. Additionally, serious adverse events associated with KRYSTEXXA therapy will be identified. Read More
Last Updated: 30 Nov 2016
Source: Alder Biopharmaceuticals, Inc.
The primary purpose of this study is to identify an appropriate dose of study medication. Read More
Last Updated: 14 Jul 2015
Source: Abbott
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs). Read More
Last Updated: 12 Aug 2006
Source: Canadian Research & Education in Arthritis
Recruited patients will include those about to begin Disease-Modifying Antirheumatic Drug) DMARD therapy or about to change DMARD therapy. Disease activity will be monitored systematically every 3 months by the Disease Activity Score. Changes in standard DMARD and/or anti-Tumor Necrosis Factor α (anti-TNFα) therapy will be made according to specific recommendations for patients receiving these therapies. Biomarker samples will be collected every 3 ... Read More
Last Updated: 15 Nov 2016
Source: Glostrup University Hospital, Copenhagen
Investigation of wholebody MRI and circulating biomarkers of inflammation, cartilage and bone metabolism in patients with spondyloarthritis treated with adalimumab. Furthermore to compare ultrasound examination with wholebody MRI etc. Read More
Last Updated: 17 Aug 2015
Source: Pfizer
This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination. Read More
Last Updated: 30 Jul 2015
Source: Diakonhjemmet Hospital
The ultimate goal of treatment in early rheumatoid arthritis (RA) is remission, i.e. an absence of signs and symptoms of the disease. However, the optimal way of reaching this goal is not known. Ultrasonography (US) is an imaging modality which application is rapidly growing. It has a number of advantages over other advanced imaging techniques such as magnetic resonance imaging (MRI), including low cost, good accessibility, and ability to scan many joints ... Read More
Last Updated: 14 Apr 2015
Page 1 of 50